Cyclosporine A shows immunosuppressor activity on T lymphocytes from the peripheral blood and synovial fluid of patients with autoimmune arthritis

This work studies the effects of Cyclosporine A (CsA) upon the activation and proliferation of mononuclear cells (MNC) from the peripheral blood (PB) of patients with chronic autoimmune arthritis and from healthy controls, and from the synovial fluid (SF) of patients. In vitro studies of activation,...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental rheumatology Vol. 14; no. 2; p. 145
Main Authors Guillen, C, Prieto, A, Perez-Blas, M, Alvarez de Buergo, M, Villa, L, Rico, H, Zea, A, Alvarez-Mon, M
Format Journal Article
LanguageEnglish
Published Italy 01.03.1996
Subjects
Antigens - analysis
Arthritis - drug therapy
Arthritis - metabolism
Arthritis - pathology
Autoimmune Diseases - drug therapy
Autoimmune Diseases - metabolism
Autoimmune Diseases - pathology
Base Sequence
Blood Cells - drug effects
Cell Cycle - drug effects
Cyclosporine - therapeutic use
Cytokines - biosynthesis
Female
Humans
Immunosuppressive Agents - therapeutic use
Interleukin-2 - genetics
Male
Molecular Probes - genetics
Molecular Sequence Data
RNA, Messenger - metabolism
Synovial Fluid - cytology
T-Lymphocytes - drug effects
Online AccessGet more information

Cover

More Information
Summary:This work studies the effects of Cyclosporine A (CsA) upon the activation and proliferation of mononuclear cells (MNC) from the peripheral blood (PB) of patients with chronic autoimmune arthritis and from healthy controls, and from the synovial fluid (SF) of patients. In vitro studies of activation, proliferation, mRNA expression and lymphokine production were carried out. We found in the PB and SF MNCs from patients with autoimmune arthritis that CsA inhibits the proliferative response, activation antigen expression, IL-2 mRNA expression and IL-2 production induced by polyclonal mitogens in a dose dependent manner. CsA blocks lymphocyte activation in PB and SF MNCs from patients with autoimmune arthritis.
ISSN:0392-856X